Albert P. Li - Transporters and Drug-Metabolizing Enzymes in Drug Toxicity

Здесь есть возможность читать онлайн «Albert P. Li - Transporters and Drug-Metabolizing Enzymes in Drug Toxicity» — ознакомительный отрывок электронной книги совершенно бесплатно, а после прочтения отрывка купить полную версию. В некоторых случаях можно слушать аудио, скачать через торрент в формате fb2 и присутствует краткое содержание. Жанр: unrecognised, на английском языке. Описание произведения, (предисловие) а так же отзывы посетителей доступны на портале библиотеки ЛибКат.

Transporters and Drug-Metabolizing Enzymes in Drug Toxicity: краткое содержание, описание и аннотация

Предлагаем к чтению аннотацию, описание, краткое содержание или предисловие (зависит от того, что написал сам автор книги «Transporters and Drug-Metabolizing Enzymes in Drug Toxicity»). Если вы не нашли необходимую информацию о книге — напишите в комментариях, мы постараемся отыскать её.

This book provides a comprehensive and up-to-date coverage of the relationship between drug metabolism enzymes and transporters on drug toxicity, along with methods to investigate their role on adverse drug reactions.
Unites both the metabolism and transporter components of drug toxicity – two aspects not normally connected and the latter often neglected Familiarizes readers with the mechanism and species differences in drug metabolizing enzymes and transporters Discusses promising approaches to accurately predict human drug toxicity via the incorporation of human drug metabolism in toxicity evaluation

Transporters and Drug-Metabolizing Enzymes in Drug Toxicity — читать онлайн ознакомительный отрывок

Ниже представлен текст книги, разбитый по страницам. Система сохранения места последней прочитанной страницы, позволяет с удобством читать онлайн бесплатно книгу «Transporters and Drug-Metabolizing Enzymes in Drug Toxicity», без необходимости каждый раз заново искать на чём Вы остановились. Поставьте закладку, и сможете в любой момент перейти на страницу, на которой закончили чтение.

Тёмная тема
Сбросить

Интервал:

Закладка:

Сделать

44 44 Chomchai S, Chomchai C. Being overweight or obese as a risk factor for acute liver injury secondary to acute acetaminophen overdose. Pharmacoepidemiol Drug Saf 2018; 27(1):19–24.

45 45 Makin A, Williams R. Paracetamol hepatotoxicity and alcohol consumption in deliberate and accidental overdose. QJM 2000; 93(6):341–9.

46 46 Banda PW, Quart BD. The effect of mild alcohol consumption on the metabolism of acetaminophen in man. Res Commun Chem Pathol Pharmacol 1982; 38(1):57–70.

47 47 Farinati F, Cardin R, de Maria N, Lecis PE, Della Libera G, Burra P, et al. Zinc, iron, and peroxidation in liver tissue. Cumulative effects of alcohol consumption and virus‐mediated damage‐‐a preliminary report. Biol Trace Elem Res 1995; 47 (1–3):193–9.

48 48 Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerivastatin‐gemfibrozil combination therapy‐‐a case report. Angiology 2000; 51(8):695–7.

49 49 Ravnan SL, Locke C, Yee WP, Haase K. Cerivastatin‐induced rhabdomyolysis: 11 case reports. Pharmacotherapy 2002; 22(4):533–7.

50 50 Rodriguez ML, Mora C, Navarro JF. Cerivastatin‐induced rhabdomyolysis. Ann Intern Med 2000; 132(7):598.

51 51 Simpson S. Case reports of rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med 2001; 161 (21):2630–1.

52 52 SoRelle R. Baycol withdrawn from market. Circulation 2001; 104(8):E9015–6.

53 53 Wooltorton E. Bayer pulls cerivastatin (Baycol) from market. CMAJ 2001; 165(5):632.

54 54 Shek A, Ferrill MJ. Statin‐fibrate combination therapy. Ann Pharmacother 2001; 35 (7–8):908–17.

55 55 Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok PY, et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. Pharmacogenet Genomics 2010; 20 (10):619–29.

56 56 Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000; 39(2):99–116.

57 57 Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits CYP2C8‐mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002; 30 (12):1352–6.

58 58 Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)‐mediated hepatic uptake and CYP2C8‐mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug‐drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311(1):228–36.

59 59 Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72(6):685–91.

60 60 Muck W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998; 56 Suppl 1:15–23; discussion 33.

61 61 Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011; 21(5):280–8.

62 62 Lucas RA, Weathersby BB, Rocco VK, Pepper JM, Butler KL. Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital. Pharmacotherapy 2002; 22(6):771–4.

63 63 Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter‐mediated hepatic uptake as a mechanism for drug‐drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304(2):610–6.

64 64 Yao Y, Toshimoto K, Kim SJ, Yoshikado T, Sugiyama Y. Quantitative analysis of complex drug‐drug interactions between cerivastatin and metabolism/transport inhibitors using physiologically based pharmacokinetic modeling. Drug Metab Dispos 2018; 46(7):924–33.

65 65 Varma MV, Lin J, Bi YA, Kimoto E, Rodrigues AD. Quantitative rationalization of gemfibrozil drug interactions: consideration of transporters‐enzyme interplay and the role of circulating metabolite gemfibrozil 1‐O‐beta‐glucuronide. Drug Metab Dispos 2015; 43(7):1108–18.

66 66 Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol 1994; 17(5):389–402.

67 67 Zupanc ML, Roell Werner R, Schwabe MS, O'Connor SE, Marcuccilli CJ, Hecox KE, et al. Efficacy of felbamate in the treatment of intractable pediatric epilepsy. Pediatr Neurol 2010; 42(6):396–403.

68 68 Heyman E, Levin N, Lahat E, Epstein O, Gandelman‐Marton R. Efficacy and safety of felbamate in children with refractory epilepsy. Eur J Paediatr Neurol 2014; 18(6):658–62.

69 69 Thakkar K, Billa G, Rane J, Chudasama H, Goswami S, Shah R. The rise and fall of felbamate as a treatment for partial epilepsy‐‐aplastic anemia and hepatic failure to blame? Expert Rev Neurother 2015; 15 (12):1373–5.

70 70 Dieckhaus CM, Thompson CD, Roller SG, Macdonald TL. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact 2002; 142 (1–2):99–117.

71 71 Pellock JM, Brodie MJ. Felbamate: 1997 update. Epilepsia 1997; 38 (12):1261–4.

72 72 Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995; 45 (3 Pt 1):456–60.

73 73 Shah YD, Singh K, Friedman D, Devinsky O, Kothare SV. Evaluating the safety and efficacy of felbamate in the context of a black box warning: a single center experience. Epilepsy Behav 2016; 56:50–3.

74 74 Egnell AC, Houston B, Boyer S. in vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 2003; 305(3):1251–62.

75 75 Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH. Pharmacokinetic interactions with felbamate. in vitro–in vivo correlation. Clin Pharmacokinet 1997; 33(3):214–24.

76 76 Kapetanovic IM, Torchin CD, Strong JM, Yonekawa WD, Lu C, Li AP, et al. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact 2002; 142 (1–2):119–34.

77 77 Kapetanovic IM, Torchin CD, Thompson CD, Miller TA, McNeilly PJ, Macdonald TL, et al. Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. Drug Metab Dispos 1998; 26 (11):1089–95.

78 78 Popovic M, Nierkens S, Pieters R, Uetrecht J. Investigating the role of 2‐phenylpropenal in felbamate‐induced idiosyncratic drug reactions. Chem Res Toxicol 2004; 17 (12):1568–76.

79 79 Roller SG, Dieckhaus CM, Santos WL, Sofia RD, Macdonald TL. Interaction between human serum albumin and the felbamate metabolites 4‐Hydroxy‐5‐phenyl‐[1,3]oxazinan‐2‐one and 2‐phenylpropenal. Chem Res Toxicol 2002; 15(6):815–24.

80 80 Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3‐carbamoyl‐2‐phenylpropionaldehyde and 2‐phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol 1996; 9(8):1225–9.

81 81 Leone AM, Kao LM, McMillian MK, Nie AY, Parker JB, Kelley MF, et al. Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem Res Toxicol 2007; 20(4):600–8.

82 82 Potschka H, Fedrowitz M, Loscher W. P‐Glycoprotein‐mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood‐brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002; 327(3):173–6.

83 83 Potschka H, Fedrowitz M, Loscher W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2‐deficient TR‐ rats. Epilepsia 2003; 44 (12):1479–86.

84 84 Amery KV. Clinical evaluation of the effects of flucloxacillin in skin and soft tissue infections in the Ivory Coast. Pharmatherapeutica 1988; 5(3):193–7.

Читать дальше
Тёмная тема
Сбросить

Интервал:

Закладка:

Сделать

Похожие книги на «Transporters and Drug-Metabolizing Enzymes in Drug Toxicity»

Представляем Вашему вниманию похожие книги на «Transporters and Drug-Metabolizing Enzymes in Drug Toxicity» списком для выбора. Мы отобрали схожую по названию и смыслу литературу в надежде предоставить читателям больше вариантов отыскать новые, интересные, ещё непрочитанные произведения.


Отзывы о книге «Transporters and Drug-Metabolizing Enzymes in Drug Toxicity»

Обсуждение, отзывы о книге «Transporters and Drug-Metabolizing Enzymes in Drug Toxicity» и просто собственные мнения читателей. Оставьте ваши комментарии, напишите, что Вы думаете о произведении, его смысле или главных героях. Укажите что конкретно понравилось, а что нет, и почему Вы так считаете.

x